Journal of NeuroVirology

, Volume 11, Issue 3, pp 265–273

Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: Results from an urban observational cohort

  • Valerio Tozzi
  • Pietro Balestra
  • Patrizia Lorenzini
  • Rita Bellagamba
  • Simonetta Galgani
  • Angela Corpolongo
  • Chrysoula Vlassi
  • Dora Larussa
  • Mauro Zaccarelli
  • Pasquale Noto
  • Ubaldo Visco-Comandini
  • Marinella Giulianelli
  • Giuseppe Ippolito
  • Andrea Antinori
  • Pasquale Narciso
Article
  • 129 Downloads

Abstract

To assess prevalence and risk factors for human immunodeficiency virus (HIV)-related neurocognitive impairment (NCI), the authors performed a 7-year survey in the period 1996 to 2002. A total of 432 patients were examined. HIV-related NCI was diagnosed in 238 patients (55.1%), meeting the HIV dementia (HIV-D) criteria in 45 (10.4%). The prevalence of both NCI and HIV-D did not change significantly during the study period. Compared with patients without NCI, patients with NCI were older (40.4 versus 38.2 years; P = .003), had a higher prevalence of positive HCV serology (61.1% versus 38.9%; P = .003), and a lower nadir CD4 cell count (156 versus 222 cells/μl; P < .001). Compared with patients seen during 1996 to 1999, patients with NCI seen during 2000 to 2002 were older (40.7 versus 38.8 years; P = .004), had a less advanced disease stage (previous acquired immunodeficiency syndrome [AIDS] 28.8% versus 65.7%; P < .001) and a higher nadir CD4 count (174 versus 132 cells/μl; P = .026). This study showed an unchanged prevalence of both HIV-related NCI and HIV-D in the period 1996 to 2002. The authors found evidences for new additional potential risk factors for HIV-related NCI (older age, lower nadir CD4 count, positive hepatitis C virus [HCV] serology), and for a change of risk factors for NCI in the late highly active antiretroviral therapy (HAART) era (older age, less advanced disease, higher nadir CD4 count).

Keywords

highly active antiretroviral therapy HIV dementia HIV infection neurocognitive impairment prevalence 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. American Academy of Neurology (1991). Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type1 (HIV-1) infection: report of a Woking Group of the American Accademy of Neurol AIDS task Force. Neurology 41: 778–785.Google Scholar
  2. Becker JT, Lopez OL, Dew MA, Aizenstein HJ (2004). Prevalence of cognitive disorders differs as a function of age in HIV virus infection. AIDS 18 (Suppl 1): S11S18.CrossRefGoogle Scholar
  3. Brew BJ (2004). Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex. AIDS 18(Suppl 1): S75-S78.CrossRefPubMedGoogle Scholar
  4. D’Arminio Monforte A, Cinque P, Mocroft A, Goebel FD, Antunes F, Katlama C, Stenz Justesen U, Vella S, Kirk O, Lundgren J (2004). Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 55: 320–328.CrossRefGoogle Scholar
  5. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ (1999). Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 13: 1249–1253.CrossRefPubMedGoogle Scholar
  6. Dore GJ, McDonald A, Li Y, Kaldor JM, Brew BJ (2003). Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 17: 1539–1545.CrossRefPubMedGoogle Scholar
  7. Ferrando S, Van Gorp W, McElhiney M, Goggin K, Sewell M, Rabkin J (1998). Highly active antiretroviral treatment in HIV infection: benefits of neuropsychological function. AIDS 12: F65-F70.CrossRefPubMedGoogle Scholar
  8. Forton DM, Thomas HC, Murphy CA, Allsop JM, Foster GR, Main J, Wesnes KA, Taylor-Robinson SD (2002). Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 35: 433–439.CrossRefPubMedGoogle Scholar
  9. Hilsabeck RC, Perry W, Hassanein TI (2002). Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 35: 440–446.CrossRefPubMedGoogle Scholar
  10. Justice AC, McGinnis KA, Atkinson JH, Heaton RK, Young C, Sadek J, Madenwald T, Becker JT, Conigliaro J, Brown ST, Rimland D, Crystal S, Simberkoff M, Veterans Aging Cohort 5-Site Study Project Team (2004). Psychiatric and neurocognitive disorders among HIV-positive and negative veterans in care: Veterans Aging Cohort Five-Site Study. AIDS 18(Suppl 1): S49-S59.CrossRefPubMedGoogle Scholar
  11. Letendre S, Cherner M, Ellis R, Marcotte T, Heaton R, McCutchan JA, Grant I. Individuals coinfected with hepatitis C (HCV) and HIV are more cognitively impaired than those with either virus alone (2002). J NeuroVirol 8(Suppl 1): 27–28.Google Scholar
  12. Lezak MD (1983). Neuropsychological assessment. New York: Oxford University Press.Google Scholar
  13. Mack KA, Ory MG (2003). AIDS and older Americans at the end of the Twentieth Century. J Acquir Immune Defic Syndr 33(Suppl 2): S68-S75.PubMedGoogle Scholar
  14. Masliah E, De Teresa RM, Mallory RE, Hansen LA (2000). Changes in pathological findings at autopsy in AIDS cases for the last 15 years. AIDS 14: 69–74.CrossRefPubMedGoogle Scholar
  15. Navia BA, Price RW (1987). The acquired immunodeficiency syndrome dementia complex as the presenting or sole manifestation of human immunodeficiency virus infection. Arch Neurol 44: 65–69.PubMedGoogle Scholar
  16. Neuenburg JK, Brodt HR, Herndier BG, Bickel M, Bacchetti P, Price RW, Grant RM, Schlote W (2002). HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 31: 171–177.PubMedGoogle Scholar
  17. Ryan EL, Morgello S, Isaacs K, Naseer M, Gerits P, The Manhattan HIV Brain Bank (2004). Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology 62: 957–962.PubMedGoogle Scholar
  18. Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Selnes OA, Miller EN, Becker JT, Cohen B, McArthur JC, Multicenter AIDS Cohort Study (2001). HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990–1998. Neurology 56: 257–260.PubMedGoogle Scholar
  19. Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K, De Marcaida JA, Cohen B, Epstein L (2002). HIV-associated cognitive impairment before and after the advent of combination therapy. J NeuroVirol 8: 136–142.CrossRefPubMedGoogle Scholar
  20. Sidtis JJ, Gatsonis C, Price RW, Singer EJ, Collier AC, Richman DD, Hirsch MS, Schaerf FW, Fischl MA, Kieburtz K, Simpson D, Koch A, Feinberg J, Dafni U, and the AIDS Clinical Trial Group (1993). Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group. Ann Neurol 33: 343–349.CrossRefPubMedGoogle Scholar
  21. Spinnler H, Tognoni G (1987). Standardizzazione e taratura italiana di test neuropsicologici. Ital J Neurol Sci 6(Suppl 8): 49–54.Google Scholar
  22. Tozzi V, Balestra P, Galgani S, Murri R, Bellagamba R, Narciso P, Antinori A, Giulianelli M, Tosi G, Costa M, Sampaolesi A, Fantoni M, Noto P, Ippolito G, Wu AW (2003). Neurocognitive performance and quality of life in patients with HIV infection. AIDS Res Hum Retrovirus 19: 643–652.CrossRefGoogle Scholar
  23. Tozzi V, Balestra P, Galgani S, Narciso P, Sampaolesi A, Antinori A, Giulianelli M, Serraino D, Ippolito G (2001). Changes in neurocognitive performance in a cohort of patients treated with HAART for 3 years. JAIDS 28: 19–27.PubMedGoogle Scholar

Copyright information

© Journal of NeuroVirology, Inc. 2005

Authors and Affiliations

  • Valerio Tozzi
    • 1
  • Pietro Balestra
    • 1
  • Patrizia Lorenzini
    • 1
  • Rita Bellagamba
    • 1
  • Simonetta Galgani
    • 2
  • Angela Corpolongo
    • 1
  • Chrysoula Vlassi
    • 1
  • Dora Larussa
    • 1
  • Mauro Zaccarelli
    • 1
  • Pasquale Noto
    • 1
  • Ubaldo Visco-Comandini
    • 1
  • Marinella Giulianelli
    • 1
  • Giuseppe Ippolito
    • 1
  • Andrea Antinori
    • 1
  • Pasquale Narciso
    • 1
  1. 1.National Institute for Infectious Diseases Lazzaro SpallanzaniRomeItaly
  2. 2.Department of NeuroscienceSan Camillo HospitalRomeItaly

Personalised recommendations